Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242.
Maddaloni E. et al, (2025), Diabetes Care, 48, e61 - e62
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Loesch DP. et al, (2025), Nature Communications, 16
Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Maddaloni E. et al, (2025), Diabetes Care, 48, 235 - 242
The Science of Diabetes and a Life of Trials: The 2024 Banting Medal for Scientific Achievement Award Lecture.
Holman RR., (2025), Diabetes, 74, 164 - 174
The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
Adler AI. et al, (2025), Lancet, 405
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction.
Marx N. et al, (2024), Eur Heart J, 45, 5117 - 5126
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Lin B. et al, (2024), Lancet Diabetes Endocrinol
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Neves JS. et al, (2024), Eur J Heart Fail
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Koychev I. et al, (2024), Alzheimers Res Ther, 16
Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
DAKIN H. et al, (2024), Medical decision making
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Gao N. et al, (2024), PharmacoEconomics
Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? insights from post-hoc analysis of EXSCEL.
Gooding KM. et al, (2024), Diabetes Res Clin Pract
Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL.
Rao VN. et al, (2024), Am Heart J, 271, 123 - 135
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Morrow LM. et al, (2024), J Diabetes, 16
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Cardoso P. et al, (2024), Diabetologia
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471